Login / Signup

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.

Eman Al SulaisTurki AlAmeel
Published in: Biologics : targets & therapy (2020)
Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.
Keyphrases
  • end stage renal disease
  • healthcare
  • rheumatoid arthritis
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • electronic health record
  • big data
  • smoking cessation
  • data analysis